.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,759,308

« Back to Dashboard

Claims for Patent: 7,759,308

Title:Microparticles comprising somatostatin analogues
Abstract: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
Inventor(s): Ahlheim; Markus (Staufen, DE), Ausborn; Michael (Lorrach, DE), Lambert; Olivier (Spechbach-le-Haut, FR), Riemenschnitter; Marc (Freiburg, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/579,186
Patent Claims: 1. Microparticles comprising cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- zl)-Phe] in free form, salt form or protected form embedded in a polymer matrix wherein the polymer matrix comprises a linear and a star polylactide-co-glycolide.

2. Microparticles according to claim 1 wherein the cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- zl)-Phe] is in pamoate salt form.

3. Microparticles according to claim 1 wherein the polymer matrix comprises a linear polylactide-co-glycolide polymer and a star polylactide-co-glycolide polymer having a weight average molecular weight of about 50,000 Da.

4. Microparticles according to claim 1 wherein the ratio of linear to star polylactide-co-glycolide is 50:50.

5. Microparticles according to claim 1 wherein the cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- zl)-Phe] is an amourphous powder having a particle size less than about 5 microns.

6. Microparticles according to claim 1 further comprising a surfactant, a porosity influencing agent and/or a basic salt.

7. A pharmaceutical composition comprising microparticles according to claim 1 and a water-based vehicle comprising a wetting agent.

8. A composition according to claim 7 wherein the wetting agent comprises a poloxamer and/or a polyoxyethylene-sorbitan-fatty acid ester.

9. A composition according to any one of claim 7 wherein the vehicle comprises a tonicity agent.

10. A composition according to any one of claim 7 wherein the vehicle comprises a viscosity increasing agent.

11. A kit comprising microparticles according to claim 1 and a water-based vehicle.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc